Hosted on MSN1mon
BMO Capital maintains Outperform on Beam Therapeutics stock
O n Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...
Business Insider1mon
RBC Capital Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of $26.00. The company’s shares closed ...